Fortress Biotech Inc
FBIO3.270USD
+0.340+11.60%
終値 02/06, 16:00（ET）15分遅れの株価
101.39M時価総額
損失額直近12ヶ月PER
詳細情報 Fortress Biotech Inc 企業名
Fortress Biotech, Inc. is a biopharmaceutical company focused on acquiring and advancing assets. The Company has eight marketed prescription pharmaceutical products and over 20 programs in development, with its majority-owned and majority-controlled partners and subsidiaries and partners and subsidiaries it founded and in which it holds significant minority ownership positions. Its portfolio is being commercialized and developed for various therapeutic areas, including oncology, dermatology, and rare diseases. Its dermatology products include Emrosi, Qbrexza, Amzeeq, Zilxi, Exelderm, Targadox, and Luxamend. Its late-stage product candidates include CUTX-101 (copper histidinate injection for Menkes disease), Triplex (cytomegalovirus (CMV) vaccine), and CAEL-101 (monoclonal antibody for AL amyloidosis). Its early and mid-stage product candidates include Dotinurad (urate transporter (URAT1) inhibitor for gout), MB-101 (IL13Rα2 CAR T Cell Program for Glioblastoma), and others.
Fortress Biotech Incの企業情報
企業コードFBIO
会社名Fortress Biotech Inc
上場日Nov 17, 2011
最高経営責任者「CEO」Rosenwald (Lindsay A)
従業員数101
証券種類Ordinary Share
決算期末Nov 17
本社所在地1111 Kane Concourse
都市BAY HARBOR ISLANDS
証券取引所NASDAQ OMX - NASDAQ BASIC
国United States of America
郵便番号33154
電話番号17816524500
ウェブサイトhttps://www.fortressbiotech.com/
企業コードFBIO
上場日Nov 17, 2011
最高経営責任者「CEO」Rosenwald (Lindsay A)
Fortress Biotech Incの経営陣
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Lindsay A. Rosenwald, M.D.
Dr. Lindsay A. Rosenwald, M.D.
Executive Chairman of the Board, President, Chief Executive Officer
Executive Chairman of the Board, President, Chief Executive Officer
4.11M
-1567515.00%
Mr. Michael S. Weiss, J.D.
Mr. Michael S. Weiss, J.D.
Executive Vice Chairman - Strategic Development, Director
Executive Vice Chairman - Strategic Development, Director
1.80M
--
Mr. Dov Klein, CPA
Mr. Dov Klein, CPA
Independent Director
Independent Director
54.76K
+27322.00%
Mr. David Jin
Mr. David Jin
Chief Financial Officer and Head of Corporate Development
Chief Financial Officer and Head of Corporate Development
13.60K
+2711.00%
Dr. Lucy Lu, M.D.
Dr. Lucy Lu, M.D.
Chief Strategy Officer
Chief Strategy Officer
5.22K
--
Dr. Jimmie Harvey, Jr., M.D.
Dr. Jimmie Harvey, Jr., M.D.
Independent Director
Independent Director
--
--
Mr. J. Jay Lobell, J.D.
Mr. J. Jay Lobell, J.D.
Independent Director
Independent Director
--
--
Mr. Malcolm I. Hoenlein, Ph.D.
Mr. Malcolm I. Hoenlein, Ph.D.
Independent Director
Independent Director
--
--
Mr. Kevin L. Lorenz, J.D.
Mr. Kevin L. Lorenz, J.D.
Independent Director
Independent Director
--
--
Ms. Jaclyn Jaffe
Ms. Jaclyn Jaffe
Investor Relations
Investor Relations
--
--
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Lindsay A. Rosenwald, M.D.
Dr. Lindsay A. Rosenwald, M.D.
Executive Chairman of the Board, President, Chief Executive Officer
Executive Chairman of the Board, President, Chief Executive Officer
4.11M
-1567515.00%
Mr. Michael S. Weiss, J.D.
Mr. Michael S. Weiss, J.D.
Executive Vice Chairman - Strategic Development, Director
Executive Vice Chairman - Strategic Development, Director
1.80M
--
Mr. Dov Klein, CPA
Mr. Dov Klein, CPA
Independent Director
Independent Director
54.76K
+27322.00%
Mr. David Jin
Mr. David Jin
Chief Financial Officer and Head of Corporate Development
Chief Financial Officer and Head of Corporate Development
13.60K
+2711.00%
Dr. Lucy Lu, M.D.
Dr. Lucy Lu, M.D.
Chief Strategy Officer
Chief Strategy Officer
5.22K
--
Dr. Jimmie Harvey, Jr., M.D.
Dr. Jimmie Harvey, Jr., M.D.
Independent Director
Independent Director
--
--
収益内訳
通貨: USD更新時刻: Wed, Apr 2
通貨: USD更新時刻: Wed, Apr 2
FY2023
FY2023Q4
FY2022
FY2022Q4
FY2021
FY2019
事業別USD
会社名
収益
比率
Targadox®
3.20M
3.79%
Exelderm®
2.40M
2.83%
Ximino®
287.00K
0.34%
会社から関連データがまだ開示されていません。
事業別
地域別
事業別USD
会社名
収益
比率
Targadox®
3.20M
3.79%
Exelderm®
2.40M
2.83%
Ximino®
287.00K
0.34%
株主
更新時刻: Sat, Jan 31
更新時刻: Sat, Jan 31
株主統計
種類
株主統計
株主統計
比率
Rosenwald (Lindsay A)
13.25%
Weiss (Michael S)
5.80%
The Vanguard Group, Inc.
3.55%
Summit Financial, LLC
1.43%
Susquehanna International Group, LLP
1.15%
他の
74.82%
株主統計
株主統計
比率
Rosenwald (Lindsay A)
13.25%
Weiss (Michael S)
5.80%
The Vanguard Group, Inc.
3.55%
Summit Financial, LLC
1.43%
Susquehanna International Group, LLP
1.15%
他の
74.82%
種類
株主統計
比率
Individual Investor
20.56%
Investment Advisor
10.15%
Investment Advisor/Hedge Fund
2.69%
Hedge Fund
1.38%
Research Firm
0.51%
Bank and Trust
0.14%
Pension Fund
0.06%
他の
64.52%
機関投資家保有株
更新時刻: Mon, Dec 8
更新時刻: Mon, Dec 8
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q4
92
4.96M
26.50%
--
2025Q3
107
4.96M
27.33%
--
2025Q2
114
4.96M
27.45%
+47.82K
2025Q1
116
4.91M
27.75%
-3.29M
2024Q4
121
4.82M
26.63%
+370.47K
2024Q3
123
4.48M
24.67%
+822.95K
2024Q2
130
3.66M
27.39%
+620.10K
2024Q1
155
3.04M
28.91%
-2.56M
2023Q4
162
4.72M
15.96%
+3.18M
2023Q3
164
1.59M
428.37%
-108.10K
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
Rosenwald (Lindsay A)
4.11M
13.25%
-1.57M
-27.60%
Apr 17, 2025
Weiss (Michael S)
1.80M
5.8%
--
--
Apr 17, 2025
The Vanguard Group, Inc.
950.33K
3.06%
+97.41K
+11.42%
Sep 30, 2025
Summit Financial, LLC
444.75K
1.43%
-571.10K
-56.22%
Sep 30, 2025
Susquehanna International Group, LLP
356.18K
1.15%
+310.54K
+680.49%
Sep 30, 2025
Shikiar Asset Management, Inc.
278.47K
0.9%
--
--
Sep 30, 2025
Geode Capital Management, L.L.C.
244.42K
0.79%
+9.63K
+4.10%
Sep 30, 2025
Northern Trust Investments, Inc.
220.64K
0.71%
+127.41K
+136.67%
Sep 30, 2025
Sculptor Capital Management, Inc
208.90K
0.67%
+208.90K
--
Sep 30, 2025
Kestra Advisory Services, LLC
196.88K
0.63%
-135.12K
-40.70%
Sep 30, 2025
詳細を見る
関連ETF
更新時刻: Sat, Dec 6
更新時刻: Sat, Dec 6
銘柄名
比率
iShares Micro-Cap ETF
0.01%
Fidelity Enhanced Small Cap ETF
0%
iShares Micro-Cap ETF
比率0.01%
Fidelity Enhanced Small Cap ETF
比率0%
配当金
過去5年間の配当金総支払額は
0.00
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし
株式分割
日付
配当落ち日
種類
比率
Oct 09, 2023
Merger
15→1
Oct 09, 2023
Merger
15→1
Oct 09, 2023
Merger
15→1
Oct 09, 2023
Merger
15→1
日付
配当落ち日
種類
比率
Oct 09, 2023
Merger
15→1
Oct 09, 2023
Merger
15→1
Oct 09, 2023
Merger
15→1
Oct 09, 2023
Merger
15→1
